-+ 0.00%
-+ 0.00%
-+ 0.00%

AGENUS’ BOT/BAL ACHIEVES 42% TWO-YEAR SURVIVAL IN REFRACTORY MSS CRC, ADVANCES TOWARD REGISTRATION WITH FDA ALIGNMENT ON PHASE 3

Reuters·07/07/2025 12:55:00

Please log in to view news